SCHEMBL4190983

SCHEMBL4190983

O=C(O)c1cc(N(Cc2cccnc2)c2ccc(OC(F)F)c(OC(F)F)c2)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.43
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
PDE4B Q07343 3/20 0.40
PDE4A P27815 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
PDK1 Q15118 6/20 0.38
JAK2 O60674 2/20 0.37
JAK1 P23458 2/20 0.37
NR3C2 P08235 1/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
HSP90AA1 P07900 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7945990 0.89 DHODH (0.44) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL4496705 0.87 MAPT (0.39) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL3131461 0.86 PDE4A (0.47) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL3128750 0.85 PDE4B (0.43) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL1159028 0.84 GRM2 (0.44) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL3132322 0.84 DHODH (0.40) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL3132313 0.84 DHODH (0.40) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL1157700 0.83 PDE4B (0.44) PDE4BPDE4APDE4CPDE4DNR3C2
SCHEMBL3126203 0.83 NAPRT (0.46) DHODHKMT2AMAPTLMNAPOLB
SCHEMBL6470005 0.82 MAPT (0.40) KMT2AMAPTLMNAPOLBPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US claimed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US claimed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A DHODH 238/4885KMT2A 1226/4885MAPT 3913/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A DHODH 238/4885KMT2A 1226/4885MAPT 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.